Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therape
资讯
2024-12-04
Takeda today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.